Looking for online definition of cholesteryl ester transfer protein in the Medical Dictionary? cholesteryl ester transfer protein explanation free. What is cholesteryl ester transfer protein? Meaning of cholesteryl ester transfer protein medical term. What does cholesteryl ester transfer protein mean?
Recent randomized controlled trials have challenged the concept that increased high density lipoprotein cholesterol (HDL-C) levels are associated with coronary artery disease (CAD) risk reduction. The causal role of HDL-C in the development of atherosclerosis remains unclear. To increase precision and to minimize residual confounding, we exploited the cholesteryl ester transfer protein (CETP)-TaqIB polymorphism as an instrument based on Mendelian randomization. The Mendelian randomization analysis was performed by two steps. First, we conducted a meta-analysis of 47 studies, including 23,928 cases and 27,068 controls, to quantify the relationship between the TaqIB polymorphism and the CAD risk. Next, the association between the TaqIB polymorphism and HDL-C was assessed among 5,929 Caucasians. We further employed Mendelian randomization to evaluate the causal effect of HDL-C on CAD based on the findings from the meta-analysis. The overall comparison of the B2 allele with the B1 allele yielded a
Treatment with probucol, a widely used lipid-lowering agent, is associated with a significant reduction of high density lipoprotein (HDL) cholesterol levels, but with an apparently improved removal of cholesteryl esters from tissues (e.g., from tendon xanthomas). The effects of probucol (500 mg twice daily) on HDL subfraction distribution and cholesteryl ester transfer activity were tested in 12 patients with stable type II hyperlipidemia [low density lipoprotein (LDL) cholesterol greater than 180 mg/dl] after a placebo-controlled cross-over trial. Probucol significantly lowered total cholesterol (-13.8%), LDL cholesterol (-9.1%), and HDL cholesterol (-30%). By rate zonal ultracentrifugation, a marked reduction of HDL2 cholesterol (-68%) was shown, whereas changes in HDL3 were less significant (-21%). These findings were confirmed by polyacrylamide gradient gel electrophoresis, typically showing a reduction or disappearance of HDL2b particles and the prevalence of particles in the HDL3a range. ...
Sarich TC, Connelly MA, Schranz DB, Ghosh A, Manitpisitkul P, Leary ET, Rothenberg P, Demarest KT, Damiano BP: Phase 0 study of the inhibition of cholesteryl ester transfer protein activity by JNJ-28545595 in plasma from normolipidemic and dyslipidemic humans. Int J Clin Pharmacol Ther. 2012 Aug;50(8):584-94. doi: 10.5414/CP201627. [PubMed:22578199 ...
LP, lipoprotein; LCAT, lecithin cholesterol acyltransferase; CETP, cholesterol ester transfer protein; ACAT, acyl-CoA cholesterol acyltransferase; DGAT, acyl-CoA diacylglycerol acyltransferase; TG, triglyceride; Chol, cholesterol; LPL, lipoprotein lipase; LRP, LDL receptor-related protein; CM, chylomicron.. LCAT plays an important role in HDL-mediated cholesterol uptake from the extrahepatic tissues and, as such, serves as a main determinant of HDL maturation and plasma HDL cholesterol level. Thus LCAT deficiency can potentially account for diminished plasma HDL cholesterol and impaired HDL maturation in CRF. In fact, plasma LCAT activity is consistently diminished in patients with ESRD. This is accompanied by a significant elevation of plasma-free cholesterol and a marked reduction in plasma esterified cholesterol concentration, providing functional evidence for diminished LCAT-dependent cholesterol esterification.. CETP mediates transfer of cholesterol ester from HDL to IDL in exchange for ...
An increase in HDL-C level by 6% reduces the incidence of cardiovascular disease by 22-24%, which is similar to the effect of reduced LDL-C level decreasing cardiovascular disease by 28%.19,20) In addition, low HDL-C level has been blamed as the main cause of recent increasing prevalence dyslipidemia in Korea.21) Though pharmacological treatment options to increase HDL-C such as cholesterol ester transfer protein (CETP) inhibitor and apo A1 mimetic peptide are under development, basic epidemiological evidences required to define HDL-C cut-off levels are still not sufficient in Korea. If the study subjects are categorized by the NCEP ATP III guideline, 43.8% of men and 23.6% of women belong to the low HDL-C group. When the ADA guideline is used, 43.8% of men and 62.6% of women have low HDL-C group; resulting in a markedly higher prevalence of low HDL-C level in women. Musha et al.5) from Japanproposes a higher cut-off value of HDL-C of 50 mg/dL so that the prevalence of cardiovascular diseases in ...
Importance: Some cholesteryl ester transfer protein (CETP) inhibitors lower low-density lipoprotein cholesterol (LDL-C) levels without reducing cardiovascular events, suggesting that the clinical benefit of lowering LDL-C may depend on how LDL-C is lowered. Objective: To estimate the association between changes in levels of LDL-C (and other lipoproteins) and the risk of cardiovascular events related to variants in the CETP gene, both alone and in combination with variants in the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) gene. Design, Setting, and Participants: Mendelian randomization analyses evaluating the association between CETP and HMGCR scores, changes in lipid and lipoprotein levels, and the risk of cardiovascular events involving 102 837 participants from 14 cohort or case-control studies conducted in North America or the United Kingdom between 1948 and 2012. The associations with cardiovascular events were externally validated in 189 539 participants from 48 studies conducted ...
The paper describing the Einstein study is published in the January 13 edition of the Journal of the American Medical Association. Most work on the genetics of Alzheimers disease has focused on factors that increase the danger, said Richard B. Lipton, M.D., the Lotti and Bernard Benson Faculty Scholar in Alzheimers Disease and professor and vice chair in the Saul R. Korey Department of Neurology at Einstein and senior author of the paper. As an example, he cites APOE ε4, a gene variant involved in cholesterol metabolism that is known to increase the risk of Alzheimers among those who carry it.. We reversed this approach, says Dr. Lipton, and instead focused on a genetic factor that protects against age-related illnesses, including both memory decline and Alzheimers disease.. In a 2003 study, Dr. Lipton and his colleagues identified the cholesteryl ester transfer protein (CETP) gene variant as a longevity gene in a population of Ashkenazi Jews. The favorable CETP gene variant ...
A third of people have genetic variations that cut their risk of heart disease, perhaps by increasing the level of good (HDL) cholesterol in their blood, say UK and Dutch scientists. A new study, published in the Journal of the American Heart Association, shows that individuals with particular versions of the CETP (Cholesteryl Ester Transfer Protein) gene have a five per cent lower risk of having a heart attack.. The researchers combined the results of almost 100 other studies, involving a total of 147,000 people. They looked at six different versions of the CETP gene, and found that the three most common were associated with both a 3-5 per cent rise in the levels of HDL cholesterol and a lower risk of heart disease. High levels of LDL (bad) cholesterol increase the risk of a heart attack or stroke, as it can build up in the arteries that feed the heart and brain, making them narrower. In contrast, higher levels of HDL cholesterol seem to protect against these conditions, possibly because it ...
Consequently, multiple pharmaceutical agents have been studied with the goal of increasing HDL-C. Niacin, the most widely used medication to raise HDL-C, increases HDL-C by 25% or more and was shown in multiple surrogate endpoint studies to reduce CV risk. However, two large randomized controlled trials of niacin, AIM-HIGH and HPS2-THRIVE, have shown that despite its effects on HDL-C, niacin does not decrease the incidence of CV events and may have significant adverse effects. Studies of other classes of agents such as cholesteryl ester transfer protein (CETP) inhibitors have also shown that even dramatic increases in HDL-C do not necessarily translate to reduction in clinical events. One of the latest attempts was described by Barter and colleagues who reported the results of the CHI-SQUARE study (Can HDL Infusions Significantly Quicken Atherosclerosis Regression) study, which is the largest randomized clinical trial to date testing the efficacy of serial HDL infusions in patients with a recent ...
Human phospholipid transfer protein (PLTP) mediates the transfer of lipids among atheroprotective high-density lipoproteins (HDL) and atherogenic low-density lipoproteins (LDL) by an unknown mechanism. Delineating this mechanism would be an important step toward the understanding and regulation of PLTP for treating cardiovascular diseases, hypoalphalipoproteinemia and hyperalphalipoproteinemia. Using electron microscopy, negative-staining, and single-particle image processing, we discovered that PLTP penetrates each class of HDL, LDL and liposome independently, and also bridges a ternary complex with one of its distal end-domains penetrating into HDL and another distal domain interacting with LDL. These new insights into PLTP interaction with lipoproteins and liposomes provide a molecular basis for analyzing PLTP-dependent lipid transfer between lipoprotein particles. ...
Hollenbach, B., Schreiber, L., Hartung, W., & Dietz, K. - J. (1997). Cadmium leads to stimulated expression of the lipid transfer protein genes in barley: Implications for the involvement of lipid transfer proteins in wax assembly. Planta, 203(1), 9-19. doi:10.1007/ ...
In patients with HoFH, lomitapide led to a significant reduction of LDL-c levels and to achievement of EAS targets in many patients, while CV event rates correlated with LDL-c levels.
Developing new pharmacotherapies for cardiovascular disease is of paramount importance but a time-consuming, costly endeavor. Agents that increase high-density lipoprotein levels appeared initially attractive, but recent experience with the cholesterylesterase transfer protein (CETP) inhibitor torcetrapib was associated with increased mortality attributed to off-target effects. Dalcetrapib, a new CETP inhibitor, was tested in the phase 2b, randomized, double-blind, placebo-controlled dal-PLAQUE (A Study of the Effect of Dalcetrapib on Atherosclerotic Plaque in Patients with Coronary Heart Disease) trial that included atheroma characterization endpoints by serial carotid MRI and FDG PET imaging (12). At 6 months, dalcetrapib increased high-density lipoprotein levels by 34%. PET imaging demonstrated a modest nonsignificant trend towards decreased carotid FDG activity compared with controls (−7.3% TBR reduction, 90% confidence interval: −13.5 to −0.8). Serial MRI, however, showed a relative ...
In this paper, researchers used random segregation of genetic variants in CETP and HMGCR genes (Mendelian Randomization) to study their causal effects of on metabolic markers apolipoprotein B (apoB) and LDL-C.
1259393-05-9 - SNDKWXRGPMCSQJ-AWQMOBFQSA-N - Evacetrapib monohydrate - Similar structures search, synonyms, formulas, resource links, and other chemical information.
Cardiovascular risk is increased in hypopituitary patients. No data are available with respect to the effect of glucocorticoid replacement therapy on high density lipoproteins (HDL) metabolism in such patients. Plasma lecithin:cholesterol acyl transferase (LCAT), cholesteryl ester transfer protein (CETP) and phospholipid transfer protein (PLTP) are important determinants of HDL remodelling. The possible influence of conventional glucocorticoid replacement on plasma lipids, plasma LCAT, CETP and PLTP activity levels, as well as on plasma cholesterol esterification (EST) and cholesteryl ester transfer (CET) was evaluated in 24 consecutive hypopituitary patients (12 men and 12 women) with untreated growth hormone deficiency of whom 17 had adrenal insufficiency and were treated with cortisone acetate, 25 to 37.5 mg daily. Twenty-three patients were on stable levothyroxin therapy and 22 patients used sex steroids. Urinary excretion of cortisol and cortisone metabolites was higher (p,0.001) in ...
The author retains copyright ownership and moral rights in this thesis. Neither the thesis nor substantial extracts from it may be printed or otherwise reproduced without the authors permission ...
Despite the long-held knowledge of an inverse relationship between plasma high-density lipoprotein (HDL) cholesterol levels and rates of cardiovascular disease (CVD) in populations, the HDL hypothesis has recently been shaken to its foundations by a barrage of controversial data. For example, clinical trials of an agent (torcetrapib) that increases HDL cholesterol by inhibiting cholesteryl ester transfer protein (CETP), an essential transferase that moves cholesterol from HDL to apolipoprotein B (apo B)-containing lipoproteins, have shown unexpected harm with increased cardiovascular events after ,1 year of treatment among subjects who were already taking protective doses of atorvastatin (1). In addition, coronary and carotid imaging studies with the same agent failed to show vascular improvements attributable to the drug or to the increase in HDL cholesterol (2,3). Moreover, genetic studies have challenged the role of HDL in atherogenesis by providing observations contrary to the dogma that HDL ...
A wheat non specific phospholipid transfer protein has been isolated from wheat seeds and its amino acid sequence reveals that it is composed of 90 residues for a molecular weight of 9607. From the comparison of its sequence with those of the eight known proteins of the same family, hypotheses on the role of some conserved residues in the transfer activity can be made. The conformation of this protein has been studied by Raman and Fourier transform infrared spectroscopy and this is the first report on the structure of non specific plant phospholipid transfer proteins. As opposed to previous studies on the structure prediction from the amino acid sequence, the results obtained show that plant non specific phospholipid transfer proteins are not almost entirely composed of beta-sheets. Instead, infrared results show that the wheat protein contains 41% alpha-helix and 19% beta-sheet structures, while 40% of the conformation is undefined or composed of turns. Raman spectroscopy shows that three disulfide
We examined whether postprandial (PP) chylomicrons (CMs) can serve as vehicles for transporting cholesterol from endogenous cholesterol-rich lipoprotein (LDL+HDL) fractions and cell membranes to the liver via lecithin:cholesterol acyltransferase (LCAT) and cholesteryl ester transfer protein (CETP) activities. During incubation of fresh fasting and PP plasma containing [(3)H]cholesteryl ester (CE)-labeled LDL+HDL, both CMs and VLDL served as acceptors of [(3)H]CE or cholesterol from LDL+HDL. The presence of CMs in PP plasma suppressed the ability of VLDL to accept [(3)H]CE from LDL+HDL. In reconstituted plasma containing an equivalent amount of triglycerides from isolated VLDL or CMs, a CM particle was about 40 times more potent than a VLDL particle in accepting [(3)H]CE or cholesterol from LDL+HDLs. When incubated with red blood cells (RBCs) as a source for cell membrane cholesterol, the cholesterol content of CMs, VLDL, LDL, and HDL in PP plasma increased by 485%, 74%, 13%, and 30%, ...
Background. Dirlotapide causes body weight reduction in obese dogs primarily due to reductions in food intake.. Aims. To investigate the efficacy and safety of dirlotapide in overweight Labradors in two masked, parallel-design studies. Methods. Study A: 42 dogs randomised to 0.0, 0.025, 0.05, 0.1, 0.2 or 0.4 mg dirlotapide/kg/day orally for 4 weeks. Study B: 72 dogs randomised to nine treatments: placebo (24 weeks); dirlotapide (24 weeks) followed by placebo (28 weeks); or dirlotapide (52 weeks); on diets containing 5%, 10% or 15% fat, offered in excess of maintenance requirements. Dogs were weighed and dirlotapide dose (initially 0.1 mg/kg) was adjusted monthly. After 24 weeks, dosages were reduced to stabilise body weight. Body composition (body fat, lean tissue and bone mineral content) was monitored using dual-energy x-ray absorptiometry. Multiple blood samples were collected for haematology and biochemistry.. Results. Study A: body weight and food intake decreased asymptotically with dose, ...
TY - JOUR. T1 - Protein inhibition by microinjection and RNA-mediated interference in tissue culture cells. T2 - complementary approaches to study protein function.. AU - Stout, Jane R.. AU - Rizk, Rania S.. AU - Walczak, Claire. PY - 2009. Y1 - 2009. N2 - A major goal in cell biology is to understand the molecular mechanisms of the biological process under study, which requires functional information about the roles of individual proteins in the cell. For many non-genetic model organisms researchers have relied on the use of inhibitory reagents, such as antibodies that can be microinjected into cells. More recently, the advent of RNA-mediated interference (RNAi) has allowed scientists to knockdown individual proteins and to examine the consequences of the knockdown. In this chapter we present a comparison between microinjection of inhibitory reagents and RNAi for the analysis of protein function in mammalian tissue culture cells, providing both a description of the techniques as well as a ...
Tätä artikkelia/julkaisua ei ole tallennettu Julkariin. Julkaisun tiedoissa voi kuitenkin olla linkki toisaalle tallennettuun artikkeliin/julkaisuun. ...
Cholesterylester transfer protein (CETP) modulates the composition of various lipoproteins associated with cardiovascular disease. Despite its central role in lipoprotein metabolism, its mode of action is still not fully understood. Here we present a simple way to estimate CETP-mediated lipid fluxes between different lipoprotein fractions. The model derived adequately describes the observed findings, especially regarding low- and high dense lipoproteins (LDL and HDL), delivering correlation coefficients of R2 = 0.567 (p | 0.001) and R2 = 0.466 (p | 0.001), respectively. These estimated fluxes correlate best among all other measured concentrations and lipid per lipoprotein ratios to the observed fluxes. Our model approach is independent of CETP-actions exact mechanistic mode. It is simple and easy to apply, and may be a useful tool in revealing CETPs ambiguous role in lipid metabolism. The model mirrors a diffusion-like exchange of triglycerides between lipoproteins. Cholesteryl ester and
ConclusionThe plasma cholesteryl ester fraction after a diet high in dairy was characterized by higher 15:0 levels. Concentrations of 14:0 were only higher when comparing the FA profile after a diet high in dairy when compared to a diet high in meat.Clinical trial registrationClinicalTrials.gov, NCT01314040....
Some people have questioned this, based on the results of the CETP inhibitor trials, which increased HDL cholesterol but didnt reduce cardiovascular risk. This is not a very convincing argument against the importance of HDL, and heres why: theres no reason to expect that pumping HDL particles full of extra cholesterol would reduce cardiovascular risk. One of HDLs jobs is to take cholesterol out of the artery wall and bring it to the liver for disposal. Artificially increasing the cholesterol cargo of the particle, as CETP inhibitors do, isnt going to help HDL take more cholesterol out of the artery-- if anything, it should reduce its capacity to do so. Its essentially treating a number, with no regard for the biological mechanism of action of the HDL particle. We dont yet understand how to increase the ability of the HDL particle to transport cholesterol out of the artery, but if we can enhance that process, we will probably have another effective means of protecting against heart ...
Susan Todd, writing this morning for the New Jersey Star Ledger, has a very balanced view of the Merck CETP inhibitors chances -- including the idea that Roches CETP candidate may beat Mercks to market by more than two years -- do go read it all: . . . .The drugmaker will move anacetrapib into…
There will be no CETP heart drug miracle in the works at Merck.. The pharma giant looked over a set of positive but troublesome Phase III data for its drug anacetrapib and concluded today that they will relegate it to the same graveyard that has greeted every other CETP heart drug so far.. The decision underscores a tidal shift in drug developers standards for launching a big new drug into a major market, where the data has to point to a compelling market opportunity. Failing that, marginal drugs dont stand a chance, even if they might pass muster at the FDA.. Unfortunately, after comprehensive evaluation, we have concluded that the clinical profile for anacetrapib does not support regulatory filings, said Roger Perlmutter, president of Merck Research Laboratories. During the past half-century, Merck has made numerous, important contributions to the treatment of cardiovascular disease. Our work in cardiovascular research continues.. Once upon a time, CETP offered a bright prospect for some ...
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details ...
Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement ...
PLTP antibody, C-term (phospholipid transfer protein) for FACS, IHC-P, WB. Anti-PLTP pAb (GTX81352) is tested in Human samples. 100% Ab-Assurance.
Order CETP ELISA Kits for many Reactivities. Chicken, Cow, Dog and more. Compare CETP ELISA Kits and find the right product on antibodies-online.com.
从昨天开始,四六级阅卷已经开始了 这两天主要是改短文和复合,可以说,短文的正确率很低很低 由于阅卷太累,具体得分情况注意今后我的帖子
This mutation was detected by DGGE analysis followed by direct sequencing in a CF patient carrying [delta]F508 in the other chromosome. It was found once out of 800 Italian CF chromosomes and 100 control chromosomes from Italian population. It was identified in a CF male presenting with meconium ileus and sweat test of 130 mEq/l chloride. At 13 months old, he is in very good clinical condition with growth in the normal range and no pulmonary disease ...
We have reported studies characterizing small-molecule inhibitors that selectively inhibit PLTP activity and concomitantly reduce apoB secretion. In the present study, we identified small molecules that inhibit both PLTP and MTP activities, which are known to regulate apoB secretion. This is the first report to identify dual inhibitors for PLTP and MTP activities. The discovery was not expected based on the lack of homology of PLTP and MTP at protein sequence levels. Although CETP and PLTP have 40% homology and belong to the family of lipid transfer/lipopolysaccharide-binding proteins (Tollefson et al., 1988; Day et al., 1994), none of these compounds inhibit CETP activity (Luo et al., 2010). MTP and apoB belong to the vitellogenin family of lipid transfer proteins. Read et al. (2000) predicted the three-dimensional structure of the C-terminal lipid binding cavity of MTP based on the crystal structure of lipoviellin. The lipid cavity in MTP bears a resemblance to the lipid binding domain of ...
TY - JOUR. T1 - Effects of whole grain, fish and bilberries on serum metabolic profile and lipid transfer protein activitie. T2 - A randomized trial (Sysdimet). AU - Lankinen, M. AU - Kolehmainen, Marjukka. AU - Jääskeläinen, T. AU - Paananen, J. AU - Joukamo, L. AU - Kangas, A J. AU - Soininen, P. AU - Poutanen, Kaisa. AU - Mykkänen, H. AU - Gylling, H. AU - Oresic, M. AU - Jauhiainen, M. AU - Ala-Korpela, M. AU - Uusitupa, M. AU - Schwab, U. PY - 2014. Y1 - 2014. N2 - Objective: We studied the combined effects of wholegrain, fish and bilberries on serum metabolic profile and lipid transfer protein activities in subjects with the metabolic syndrome. Methods: Altogether 131 subjects (40-70 y, BMI 26-39 kg/m ) with impaired glucose metabolism and features of the 2 metabolic syndrome were randomized into three groups with 12-week periods according to a parallel study design. They consumed either: a) wholegrain and low postprandial insulin response grain products, fatty fish 3 times a week, and ...
Lipid Transfer Proteins (LTPs) are found in plants and foods that contain plants. Lipid Transfer Protein Syndrome is an allergy affecting people who have become sensitised to LTPs.
LIPID TRANSFER PROTEINS AND MEMBRANE CONTACT SITES IN HUMAN CANCER FEBRUARY 12, 2020: Presentation from Sima Lev about the lipid transfer proteins in cancer.
lipid transfer protein: accelerates glycolipid exchange; catalyzes net transfer of glycosphingolipids from brush border membrane vesicles; also facilitates transfer of glucosyl-, galactosyl- & lactosylceramide from liposomal vesicles to red ghost cells; see also record for phospholipid exchange protein
The protein encoded by this gene is one of at least two lipid transfer proteins found in human plasma. The encoded protein transfers phospholipids from triglyceride-rich lipoproteins to high density lipoprotein (HDL). In addition to regulating the size of HDL particles, this protein may be involved in cholesterol metabolism. At least two transcript variants encoding different isoforms have been found for this gene.[1] ...
RESULTS: at 3 months, a 31.1% decrease in the mean LDL cholesterol level was observed with evacetrapib versus a 6.0% increase with placebo, and a 133.2% increase in the mean HDL cholesterol level was seen with evacetrapib versus a 1.6% increase with placebo. After 1363 of the planned 1670 primary end-point events had occurred, the data and safety monitoring board recommended that the trial be terminated early because of a lack of efficacy. After a median of 26 months of evacetrapib or placebo, a primary end-point event occurred in 12.9% of the patients in the evacetrapib group and in 12.8% of those in the placebo group (hazard ratio, 1.01; 95% confidence interval, 0.91 to 1.11; P=0.91 ...
RESULTS In the entire study group, 47 subjects had LDL phenotype A (LDL diameter ,25.75 nm) and 3 subjects had an intermediate phenotype (25.50-25.75 nm). An interrelation between LDL size and LDL triglyceride (LDL-TG) per apolipoprotein (apo) B (Spearmans rank correlation analysis; r = −0.78; P , 0.001) or LDL cholesterol ester (CE) per apoB (r = 0.58, P , 0.001) was found, and 39% of the plasma samples studied were characterized by a monodispersed LDL pattern. Furthermore, LDL diameters correlated negatively with total TGs (men: r = −0.52, P , 0.001; women: r = −0.61, P , 0.001) and positively with insulin sensitivity (total population: r = 0.54, P , 0.001). In addition, LDL size was inversely related to the [VLDL + LDL cholesterol (CH)]/HDL-CH ratio and positively to the HDL-CE/TG ratio, which were both related vice versa to CETP activity levels. A direct relation between CETP activity levels and LDL size or composition was not observed. In a linear regression analysis including ...
Progression of proteins through the secretory pathway of eukaryotic cells involves a continuous rearrangement of macromolecular structures made up of proteins and phospholipids. The protein SEC14p is essential for transport of proteins from the yeast Golgi complex. Independent characterization of th …
Janis MT; Siggins S; Tahvanainen E; Vikstedt R; Silander K; Metso J; Aromaa A; Taskinen MR; Olkkonen VM; Jauhiainen M; Ehnholm C (2004 ...
Torcetrapib ≥98% (HPLC); CAS Number: 262352-17-0; Synonym: (2R,4S)-4-((3,5-Bis-trifluoromethylbenzyl)methoxycarbonylamino)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester, CP-529,414, CP-529414; Linear Formula: C26H25F9N2O4; find Sigma-Aldrich-PZ0170 MSDS, related peer-reviewed papers, technical documents, similar products & more at Sigma-Aldrich.
The protein encoded by this gene is found in plasma, where it is involved in the transfer of cholesteryl ester from high density lipoprotein (HDL) to other lipoproteins. Defects in this gene are a cause of hyperalphalipoproteinemia 1 (HALP1). Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2013 ...
University have found that a longevity gene helps to slow age ... (CETP) gene variant as a longevity gene in a population of ... study hypothesized that the CETP longevity gene might also be associated ...
Major depression was associated with: increased MUFA and C22:5omega3 proportions and increased C20:4omega6/C20:5omega3 and C22:5omega6/C22:6omega3 ratios; lower C22:4omega6, C20:5omega3 and C22:5omega3 fractions in phospholipids; lower C18:3omega3, C20:5omega3 and total (sigma)omega3 FAs, and higher C20:4omega6/C20:5omega3 and sigmaomega6/sigmaomega3 ratios in cholesteryl esters; lower serum concentrations of phospholipids and cholesteryl esters; and a decreased OPI ...
Simona Ester Brandejsov , Dis., Praha 10, Dou ov n - esk jazyk Po d n - kurzy tv r ho psan pro d ti a ml de Prov d n redak n ch prac . - Evropsk databanka